Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Boosting the Theranostic Effect of Liposomal Probes toward Prominin-1 through Optimized Dual-Site Targeting.

Wang Y, Jia F, Wang Z, Qian Y, Fan L, Gong H, Luo A, Sun J, Hu Z, Wang W.

Anal Chem. 2019 Jun 4;91(11):7245-7253. doi: 10.1021/acs.analchem.9b00622. Epub 2019 Apr 5.

PMID:
30920798
2.

Dual-ligand α5β1 and α6β4 integrin targeting enhances gene delivery and selectivity to cancer cells.

Levine RM, Kokkoli E.

J Control Release. 2017 Apr 10;251:24-36. doi: 10.1016/j.jconrel.2017.02.017. Epub 2017 Feb 17.

PMID:
28215671
3.

A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.

Gray BP, McGuire MJ, Brown KC.

PLoS One. 2013 Aug 23;8(8):e72938. doi: 10.1371/journal.pone.0072938. eCollection 2013.

4.

Tumor targeting and imaging with dual-peptide conjugated multifunctional liposomal nanoparticles.

Rangger C, Helbok A, Sosabowski J, Kremser C, Koehler G, Prassl R, Andreae F, Virgolini IJ, von Guggenberg E, Decristoforo C.

Int J Nanomedicine. 2013;8:4659-71. doi: 10.2147/IJN.S51927. Epub 2013 Dec 5.

5.

Microfluidic self-assembly of a combinatorial library of single- and dual-ligand liposomes for in vitro and in vivo tumor targeting.

Ran R, Wang H, Liu Y, Hui Y, Sun Q, Seth A, Wibowo D, Chen D, Zhao CX.

Eur J Pharm Biopharm. 2018 Sep;130:1-10. doi: 10.1016/j.ejpb.2018.06.017. Epub 2018 Jun 15.

PMID:
29908938
6.

Peptide-22 and Cyclic RGD Functionalized Liposomes for Glioma Targeting Drug Delivery Overcoming BBB and BBTB.

Chen C, Duan Z, Yuan Y, Li R, Pang L, Liang J, Xu X, Wang J.

ACS Appl Mater Interfaces. 2017 Feb 22;9(7):5864-5873. doi: 10.1021/acsami.6b15831. Epub 2017 Feb 9.

PMID:
28128553
7.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
8.

Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.

Chi YH, Hsiao JK, Lin MH, Chang C, Lan CH, Wu HC.

Theranostics. 2017 Apr 10;7(6):1612-1632. doi: 10.7150/thno.17573. eCollection 2017.

9.

Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.

Belhadj Z, Ying M, Cao X, Hu X, Zhan C, Wei X, Gao J, Wang X, Yan Z, Lu W.

J Control Release. 2017 Jun 10;255:132-141. doi: 10.1016/j.jconrel.2017.04.006. Epub 2017 Apr 6.

PMID:
28390902
10.

Design of Multifunctional Liposomal Nanocarriers for Folate Receptor-Specific Intracellular Drug Delivery.

Kang MH, Yoo HJ, Kwon YH, Yoon HY, Lee SG, Kim SR, Yeom DW, Kang MJ, Choi YW.

Mol Pharm. 2015 Dec 7;12(12):4200-13. doi: 10.1021/acs.molpharmaceut.5b00399. Epub 2015 Nov 6.

PMID:
26544061
11.

PR_b-targeted PEGylated liposomes for prostate cancer therapy.

Demirgöz D, Garg A, Kokkoli E.

Langmuir. 2008 Dec 2;24(23):13518-24. doi: 10.1021/la801961r.

PMID:
18954096
12.

Enhanced active targeting via cooperative binding of ligands on liposomes to target receptors.

Sugiyama T, Asai T, Nedachi YM, Katanasaka Y, Shimizu K, Maeda N, Oku N.

PLoS One. 2013 Jun 28;8(6):e67550. doi: 10.1371/journal.pone.0067550. Print 2013.

13.

From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.

Gray BP, Li S, Brown KC.

Bioconjug Chem. 2013 Jan 16;24(1):85-96. doi: 10.1021/bc300498d. Epub 2013 Jan 7.

14.

Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.

Shahin M, Soudy R, Aliabadi HM, Kneteman N, Kaur K, Lavasanifar A.

Biomaterials. 2013 May;34(16):4089-4097. doi: 10.1016/j.biomaterials.2013.02.019. Epub 2013 Mar 5.

PMID:
23465829
15.

Targeted delivery of transferrin and TAT co-modified liposomes encapsulating both paclitaxel and doxorubicin for melanoma.

Yuan M, Qiu Y, Zhang L, Gao H, He Q.

Drug Deliv. 2016 May;23(4):1171-83. doi: 10.3109/10717544.2015.1040527. Epub 2015 Jun 3.

PMID:
26036724
16.
17.

Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity.

Stefanick JF, Omstead DT, Kiziltepe T, Bilgicer B.

Nanoscale. 2019 Mar 7;11(10):4414-4427. doi: 10.1039/c8nr09431d.

PMID:
30801591
18.

Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.

Tang J, Zhang L, Liu Y, Zhang Q, Qin Y, Yin Y, Yuan W, Yang Y, Xie Y, Zhang Z, He Q.

Int J Pharm. 2013 Sep 15;454(1):31-40. doi: 10.1016/j.ijpharm.2013.06.048. Epub 2013 Jul 10.

PMID:
23850793
19.

Dual-targeting peptide probe for sequence- and structure-sensitive sensing of serum albumin.

Yu Y, Huang Y, Jin Y, Zhao R.

Biosens Bioelectron. 2017 Aug 15;94:657-662. doi: 10.1016/j.bios.2017.03.067. Epub 2017 Apr 2.

PMID:
28390316
20.

Development of the novel PEG-PE-based polymer for the reversible attachment of specific ligands to liposomes: synthesis and in vitro characterization.

Biswas S, Dodwadkar NS, Sawant RR, Torchilin VP.

Bioconjug Chem. 2011 Oct 19;22(10):2005-13. doi: 10.1021/bc2002133. Epub 2011 Sep 12.

Supplemental Content

Support Center